PalanerFree on the App Store
Get
Longevity Biotech Pitch Night — New York
WorkFree

Longevity Biotech Pitch Night — New York

Thursday 19 November 2026, 17:00Venue time (New York)
FreeTickets sold by luma.com
Book · Freevia luma.com
Add to calendar

Downloads an .ics file · Times are in America/New_York · Google Calendar

Longevity Biotech Pitch Night — New YorkHosted by the Longevity Investor Network & Lifespan Research Institute
When: Thursday, November 19, 2026Where: [RSVP to see venue], New York City
About the Event
Join us for an exclusive evening in New York as we showcase some of the most promising longevity startups shaping the future.
A handpicked group of companies will take the stage to share their vision, scientific breakthroughs, and growth potential in front of a curated audience of leading investors. This is a unique opportunity to get a first look at innovative ventures before they make their mark.
What to Expect
✨ Startup Pitches – Hear directly from founders building the next big thing in longevity.🤝 Investor-Only Access – An intimate, invite-only setting designed for meaningful connections.🏛 [Venue Highlight] – Network and discover new ideas at [venue name/description].
Agenda (times TBD)
5:00PM - 6:20PM: Registration / Networking
6:20PM - 6:30PM: Opening Remarks — Keith Comito (LRI/LIN)
6:30PM - 6:50PM: Repair Biotechnologies Presentation
6:50PM - 7:10PM: Unmask Therapeutics Presentation
7:10PM - 7:30PM: Havia Bio Presentation
7:30PM - 7:55PM: Break / Networking
7:55PM - 8:00PM: A few words from our CEO (LRI/LIN)
8:00PM - 8:20PM: Repairon Presentation
8:20PM - 8:40PM: Sapere Bio Presentation
8:40PM - 9:15PM: Break / Networking / Clean-up
Who's Pitching
Repair Biotechnologies: Repair Biotechnologies develops the proprietary Cholesterol Degrading Platform (CDP) that clears toxic excess free cholesterol inside cells, an undruggable target that existing therapies cannot meaningfully address. Cardiovascular disease accounts for ~27% of global mortality. Current treatments slow plaque growth but cannot reverse it. Repair’s lead drugs have demonstrated 20–30% plaque regression and 100% gain in treadmill endurance in just 6 weeks in preclinical models of severe atherosclerosis, improvements that continue to grow after treatment cessation. The company has completed a successful non-human primate study showing safety and favorable metabolic changes, has received FDA Orphan Drug Designation, and held a positive pre-IND meeting with the FDA. The pipeline extends to MASH (liver disease), neurodegeneration, and ocular conditions. The company was recently awarded Rare Disease Evidence Principles (RDEP) program eligibility by the FDA, allowing for drug approval after a single clinical trial.
Unmask Therapeutics: Unmask Therapeutics is a spinout of the Lifespan Research Institute developing a novel small-molecule therapeutic for genetic mitochondrial diseases, with the potential to address an underlying cause of disease rather than just manage symptoms. Its initial target market is patients with rare, severe mitochondrial disorders, an area of significant unmet medical need, with potential longer-term applications in broader mitochondrial dysfunction and age-related disease. They currently have strong in-vitro efficacy data and in-vivo pharmacokinetics, and working on pivotal preclinical in-vivo efficacy study in disease-model mice.
Havia Bio is building the missing delivery layer for regenerative medicine. Many promising biologics, from peptides and growth factors to exosomes and stem cells, clear from the body before they can work. Havia’s HYALUTE™ platform uses engineered hyaluronic acid microparticles to keep therapies at the target site and release them steadily over one to six months. Its lead product, VIA101 is a once-a-month, non-hormonal vaginal film for genitourinary syndrome of menopause. GSM affects an estimated 17 million postmenopausal women, and most of those who seek treatment are dissatisfied with current options. Havia has clean safety data in two large-animal species and five patent applications. It is working toward FDA De Novo clearance for VIA101 while advancing platform applications in sports medicine, ophthalmology, aesthetics, and cardiovascular disease.
Repairon is developing lab-grown heart muscle to repair failing hearts, one of the few companies to bring induced pluripotent stem cell (iPSC)-derived tissue into patients. Its lead product, BioVAT, is a contractile patch of engineered human heart muscle, implanted onto the damaged heart to rebuild the muscle that heart attacks and heart failure destroy. Today’s heart failure drugs can only slow decline, and transplants reach very few patients. In a Phase 1/2 trial published in the New England Journal of Medicine, patients at the highest dose saw their damaged heart walls thicken by 4.5 mm and their heart pumping function improve within three months, along with better quality of life. The patches integrated with the patient’s heart, formed their own blood supply and beat in sync with it. A Phase 2 trial is underway, and the same tissue-engineering platform is being extended to other organs, starting with an immunology spinoff.
Sapere Bio is a commercial-stage longevity diagnostics company making immune health measurable and actionable. Its flagship product, SapereX Longevity, measures six domains of immune resilience giving physicians unprecedented visibility into individual immune vulnerabilities and the ability to make more precise intervention decisions —identifying which patients may benefit, which interventions may be inappropriate, and how to prioritize and monitor treatment over time. Built on 34 clinical studies and $5.9 million in NIH funding, SapereX has demonstrated its ability to reveal immune dysfunction even when conventional laboratory results appear normal. The test is already commercial, available in 47 states, and runs in the company’s own CAP/CLIA lab. The company has delivered more than 1,600 tests and established a growing base of paying longevity clinics, with strong repeat testing and customer retention. Sapere is now positioned to scale commercial adoption and build the clinical evidence and intervention-response data needed to replace trial-and-error longevity care with interventions guided by measurable immune biology.

Event Details
📅 Date: Thursday, November 19, 2026📍 Location: [RSVP to see venue], New York City🎟 Audience: Invite-only for investors
🤝 Investor Attendees:Investors From: Longevity Investor Network, Age1, ContinuumHealthVC, DraperVC, LunarVentures, NFX, PioneerFundVC, PearVC, InsightPartners, XPrize, OutsidersFund, HCVC, BackedVC, LongevityTechFund, Longevity Vision Fund, BoxOne Ventures, SOSV NY, Maximon, Juvenescence, 5AM Ventures, CambrianBio, AltosLabs, Canaan Partners, LongeVC, Methuselah Foundation, CurieBio, Centenarian Fund, Formic Ventures, Khosla Ventures, Prime Movers Lab, Life Science Angels, Emerging Longevity Ventures, HOF Capital, OrbiMed, Apollo Health Ventures, and more!
Register Your Interest
If you've received an invitation, please RSVP to confirm your spot. Space is limited.
By registering for this event, you’ll join our mailing list for updates about this and future LRI events. You can unsubscribe at any time.
Lifespan Research Institute ("LRI") is a 501(c)(3) nonprofit organization focused on the defeat of age-related disease and the extension of healthy human lifespan – through raising funds and awareness for scientific work addressing the root causes of the aging process, building a thriving ecosystem of mission aligned stakeholders which can be mobilized to strategic action, and spearheading relevant research projects directly. We work to identify, develop, and promote initiatives with outsized impact and the greatest potential to realize widespread access to regenerative medicine solutions targeting the disabilities and diseases of aging.
Lifespan.io Sponsors & Members of the Lifespan AllianceWe are deeply honored by and grateful for the support of our Lifespan Alliance members, whose contributions are integral to our mission to extend healthy human lifespan and overcome age-related disease. Join the Lifespan Alliance today: https://www.lifespan.io/get-involved/become-a-sponsor/
The Longevity Investor Network is an initiative of Lifespan Research Institute, a 501(c)(3) nonprofit formed through the merger of SENS Research Foundation and Lifespan.io.
As a 501(c)3 nonprofit, your support is vital to our mission at LRI — consider making a donation: https://www.lifespan.io/how-you-can-help/ to help us continue advancing longevity science and hosting impactful events like this one.
For more information on how to join the Longevity Investor Network, please reach out to [email protected]

Ask Palaner

Going to Longevity Biotech Pitch Night? Ask me anything about it.

I read the organiser's pages and answer in a few seconds.

Answers are AI-generated · Privacy